Time to resolution of iodine‐123 metaiodobenzylguanidine ( <scp> <sup>123</sup> I‐MIBG </scp> ) avidity and local control outcomes for high‐risk neuroblastoma following radiation therapy-Reference-Cited by-同舟云学术

Time to resolution of iodine‐123 metaiodobenzylguanidine ( ¹²³ I‐MIBG ) avidity and local control outcomes for high‐risk neuroblastoma following radiation therapy

Published:2022-10-27 Issue:1 Volume:67 Page:81-88
ISSN:1754-9477
Container-title:Journal of Medical Imaging and Radiation Oncology
language:en
Short-container-title:J Med Imag Rad Onc

Author:

Oh Justin¹,Gutkin Paulina¹^ORCID,Wang Yi Peng¹,Sandhu Navjot¹,Majzner Robbie G²,Nadel Helen³,Shimada Hiroyuki⁴,Lansinger Olivia¹^ORCID,von Eyben Rie¹,Donaldson Sarah¹,Bruzoni Matias⁵,Sodji Quaovi H¹,Hiniker Susan M¹^ORCID

Affiliation:

1. Department of Radiation Oncology Stanford University Stanford California USA

2. Division of Hematology/Oncology, Department of Pediatrics Stanford University Stanford California USA

3. Department of Radiology Stanford University Stanford California USA

4. Department of Pathology Stanford University Stanford California USA

5. Department of Surgery Stanford University Stanford California USA

Publisher

Wiley

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1754-9485.13487

Reference28 articles.

1. Molecular Imaging of Neuroendocrine Tumors

2. MIBG in neuroblastoma diagnosis and treatment

3. MIBG in Neuroblastoma Diagnostic Imaging and Therapy

4. Correlation of Early Metastatic Response by123I-Metaiodobenzylguanidine Scintigraphy With Overall Response and Event-Free Survival in Stage IV Neuroblastoma

5. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children’s Oncology Group ANBL0532 Study